Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine
< b > Conditions < /b > : Meningitis; Meningococcal Meningitis; Meningococcal Infections < br/ > < b > Interventions < /b > : Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; Biological: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine < br/ > < b > Sponsor < /b > : Sanofi Pasteur, a Sanofi Company < br/ > < b > Recruiting < /b > - verified July 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ActHIB | Diphtheria | Men | Meningitis | Meningitis Vaccine | Research | Tetanus | Tetanus Vaccine | Vaccines